Share Purchase

RNS Number:8934T
Napo Pharmaceuticals Inc.
07 May 2008

For immediate release                                                7 May 2008

                       Napo Pharmaceuticals Inc.
                       ("Napo" or "the Company")

                             Share Purchase


Notification of Transactions of Directors, Persons Discharging Managerial
Responsibility or Connected Persons



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR
FROM THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN



South San Francisco, California,   7 May 2008 - South San Francisco, California,
Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU), announces that in relation to
transactions of Directors and Persons Discharging Managerial Responsibility, it
was informed on 6 May 2008 that Dr. Steven King, VP Ethnobotanical Research,
Supply and IP, purchased 75,000 Common Shares (LSE: NAPL) at a price of 5.75
pence per share.



These shares were purchased on 30 April 2008. Following the purchase of these
Common Shares, Steven King has a total personal holding of 154,116 Common Shares
in the Company amounting to 0.3 per cent of the issued share capital.



Dr. King has a deemed interest in 183,344 shares of Common Shares which are held
by Thad R Partridge Trustee for the Steven R King 2006 Children's Trust.    This
is an irrevocable trust.


For more information please contract:

Napo Pharmaceuticals, Inc.
Lisa Conte, Chief Executive Officer
(001) + 650 616 1902

Charles Thompson, Chief Financial Officer
(001) + 650 616 1903

Buchanan Communications
(44) + 020 7466 5000
Tim Anderson, Mary-Jane Johnson, Catherine Breen


About Napo Pharmaceuticals, Inc.


Napo Pharmaceuticals, Inc. focuses on the development and commercialisation of
proprietary pharmaceuticals for the global marketplace in collaboration with
local partners. Napo was founded in November 2001, and is based in California,
USA with a subsidiary in Mumbai, India.



Napo's late-stage proprietary gastro-intestinal compound, crofelemer, is in
various stages of clinical development for four distinct product indications,
including a late-stage Phase 3 program:



   CRO-HIV for AIDS diarrhoea, Phase 3

   CRO-IBS for diarrhoea irritable bowel syndrome ("D-IBS"), Phase 2

   CRO-ID for acute infectious diarrhoea (including cholera), Phase 2

   CRO-PED for paediatric diarrhoea, Phase 1



The FDA has granted fast-track status to CRO-IBS and CRO-HIV.



Crofelemer, a proprietary patented agent, is extracted from Croton lechleri, a
medicinal plant which can be sustainably harvested from several countries in
South America. Napo also plans to develop an early clinical stage product,
NP-500, for the treatment of insulin resistant diseases of Type II diabetes and
metabolic syndrome (Syndrome X; pre-diabetic syndrome). Napo also has a plant
library of approximately 2,300 medicinal plants from tropical regions, and Napo
has entered two screening relationship associated with this collection.



Currently, products are based on the chemical and biological diversity derived
from plants with medicinal properties, but future products may be in-licensed
from other sources.



Napo has partnerships with Glenmark Pharmaceuticals Limited of India and
AsiaPharm Group Ltd. of China.



For more information please visit www.napopharma.com.








                      This information is provided by RNS
            The company news service from the London Stock Exchange

END

MSCARMJTMMJMBMP